ArticleScientific reports2026
Plasma proteomic signatures associated with abdominal aortic aneurysm presence, growth, and risk of mortality.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Human Transcriptomic Meta-Analysis Identifies Immune-Redox Remodeling and Impaired Vascular Wall Homeostasis in Abdominal Aortic Aneurysm.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal aortic aneurysm is a vascular disorder, often diagnosed incidentally, that poses substantial morbidity and mortality. Current risk assessment relies heavily on imaging and conventional risk factors. This study aimed to evaluate associations between plasma proteins and abdominal aortic aneurysm presence, progression, and mortality. A nested case-control cohort of 641 men aged 65-74 years from the Viborg Vascular screening trial (VIVA) with available plasma samples underwent proteomic profiling using mass spectrometry-based proteomics; 466 were abdominal aortic aneurysm cases, 175 were age-matched controls. Associations between individual protein levels and (1) presence of abdominal aortic aneurysm, (2) annual aneurysm growth, and (3) time-to-death were evaluated using multivariable regression models adjusted for clinical risk factors with correction for multiple testing by controlling the false discovery rate. Plasma proteins significantly associated with outcomes were further evaluated for added predictive value. Twenty-seven plasma proteins, including coagulation factor XIIIa and complement factor H, were independently associated with the presence of abdominal aortic aneurysm and significantly improved prediction beyond common risk factors (ΔAUC + 0.11, P = 0.00024). An exploratory 22-protein panel combined with diabetes status, smoking, and baseline aortic diameter improved discrimination between slow- and fast-growing aneurysms compared with aortic diameter alone (ΔAUC + 0.09, P = 0.0020). Thirteen proteins were independently associated with time-to-death and improved mortality prediction beyond clinical factors (Δc-statistics + 0.13, P = 4.07E-6). Proteomic profiling identified plasma proteins that were independently associated with abdominal aortic aneurysms presence, progression, and mortality, provided significant discrimination between slow- and fast-growing aneurysms, and improved prediction of mortality beyond established risk factors. In all supporting the potential role of plasma proteins in complementing risk stratification of abdominal aortic aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.